TLR8 and ovarian carcinoma: Monk et al. reported that combining a Toll-like receptor 8 (TLR8) agonist with pegylated liposomal DOX significantly inhibited the growth of ovarian carcinoma in mice with a humanized immune system (Monk et al., 2017).